1. Home
  2. ADCT vs ARTNA Comparison

ADCT vs ARTNA Comparison

Compare ADCT & ARTNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADCT
  • ARTNA
  • Stock Information
  • Founded
  • ADCT 2011
  • ARTNA 1905
  • Country
  • ADCT Switzerland
  • ARTNA United States
  • Employees
  • ADCT N/A
  • ARTNA N/A
  • Industry
  • ADCT Biotechnology: Pharmaceutical Preparations
  • ARTNA Water Supply
  • Sector
  • ADCT Health Care
  • ARTNA Utilities
  • Exchange
  • ADCT Nasdaq
  • ARTNA Nasdaq
  • Market Cap
  • ADCT 398.2M
  • ARTNA 343.5M
  • IPO Year
  • ADCT 2020
  • ARTNA 1996
  • Fundamental
  • Price
  • ADCT $3.33
  • ARTNA $33.13
  • Analyst Decision
  • ADCT Strong Buy
  • ARTNA
  • Analyst Count
  • ADCT 6
  • ARTNA 0
  • Target Price
  • ADCT $7.80
  • ARTNA N/A
  • AVG Volume (30 Days)
  • ADCT 711.4K
  • ARTNA 24.5K
  • Earning Date
  • ADCT 11-06-2025
  • ARTNA 11-03-2025
  • Dividend Yield
  • ADCT N/A
  • ARTNA 3.73%
  • EPS Growth
  • ADCT N/A
  • ARTNA 22.07
  • EPS
  • ADCT N/A
  • ARTNA 2.17
  • Revenue
  • ADCT $77,246,000.00
  • ARTNA $110,427,000.00
  • Revenue This Year
  • ADCT $12.71
  • ARTNA $6.86
  • Revenue Next Year
  • ADCT $6.59
  • ARTNA $4.46
  • P/E Ratio
  • ADCT N/A
  • ARTNA $15.21
  • Revenue Growth
  • ADCT 15.73
  • ARTNA 7.13
  • 52 Week Low
  • ADCT $1.05
  • ARTNA $29.45
  • 52 Week High
  • ADCT $3.97
  • ARTNA $38.94
  • Technical
  • Relative Strength Index (RSI)
  • ADCT 56.37
  • ARTNA 49.69
  • Support Level
  • ADCT $3.04
  • ARTNA $32.45
  • Resistance Level
  • ADCT $3.59
  • ARTNA $33.32
  • Average True Range (ATR)
  • ADCT 0.17
  • ARTNA 0.67
  • MACD
  • ADCT 0.03
  • ARTNA -0.02
  • Stochastic Oscillator
  • ADCT 55.65
  • ARTNA 37.16

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About ARTNA Artesian Resources Corporation

Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.

Share on Social Networks: